David Jorden
Net worth: 2 M $ as of 2026-06-29
Net worth: 2 M $ as of 2026-06-29
Mr. David E.
Jorden, CFA MBA, is a Chief Executive Officer & Director at Nanospectra Biosciences, Inc. and a CEO, CFO, Secretary & Director at Nuo Therapeutics, Inc. He is on the Board of Directors at Nanospectra Biosciences, Inc. and Nuo Therapeutics, Inc. Mr. Jorden was previously employed as a Chief Financial Officer by PLx Pharma, Inc., a Vice President by Morgan Stanley, a Chief Financial Officer & Vice President by Genometrix, Inc., a Principal by Fayez Sarofim & Co. LLC, and a Chief Financial Officer & Director by PLx Pharma, Inc. /Old/.
He also served on the board at Opexa Therapeutics, Inc. He received his undergraduate degree from The University of Texas at Austin and an MBA from Kellogg School of Management.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NUO THERAPEUTICS INC 4.26% | 2026-06-29 | 2,061,227 ( 4.26% ) | 2 M $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| NUO THERAPEUTICS, INC. | Chief Executive Officer | 2016-01-07 |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic and diagnostic products | Chief Executive Officer | 2013-05-31 |
| Companies | Position | End |
|---|---|---|
| PLX PHARMA WINDDOWN CORP. | Director of Finance/CFO | 2017-06-30 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops autologous personalized cell therapies for the treatment of various diseases. | Director of Finance/CFO | 2013-04-01 |
| MORGAN STANLEY | Corporate Officer/Principal | - |
Genometrix, Inc.
Genometrix, Inc. Miscellaneous Commercial ServicesCommercial Services Performs commercial physical and biological research | Director of Finance/CFO | 2002-08-31 |
Fayez Sarofim & Co. LLC
Fayez Sarofim & Co. LLC Investment ManagersFinance FSC is a long-term investor which seeks to generate sustainable earnings growth by dominantly investing in large-cap companies. The firm employs a predominantly bottom-up investment decision-making process managed by the Investment Committee. The committee formulates a macroeconomic and capital market outlook and evaluates the attractiveness of the various economic sectors and industries. | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 10 |
|---|---|
Morgan Stanley
Morgan Stanley Investment ManagersFinance Provides wealth and asset management, trading & investment banking services | Finance |
Fayez Sarofim & Co. LLC
Fayez Sarofim & Co. LLC Investment ManagersFinance FSC is a long-term investor which seeks to generate sustainable earnings growth by dominantly investing in large-cap companies. The firm employs a predominantly bottom-up investment decision-making process managed by the Investment Committee. The committee formulates a macroeconomic and capital market outlook and evaluates the attractiveness of the various economic sectors and industries. | Finance |
Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops drugs for the treatment of chronic wounds | Health Technology |
Genometrix, Inc.
Genometrix, Inc. Miscellaneous Commercial ServicesCommercial Services Performs commercial physical and biological research | Commercial Services |
PLx Pharma, Inc. /Old/
PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology Develops formulations of non steroidal anti-inflammatory drugs | Health Technology |
The University of Texas at Austin
The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic and diagnostic products | Health Technology |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops autologous personalized cell therapies for the treatment of various diseases. | Health Technology |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PLx Pharma, Inc.
PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops liquid-filled aspirin capsules for pain management | Health Technology |
Select your edition
All financial news and data tailored to specific country editions